Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Multicenter Study
. 2007 Oct;96(10):738-42.
doi: 10.1007/s00392-007-0553-5. Epub 2007 Aug 17.

Distal embolic protection during percutaneous intervention of aorto-coronary venous bypass grafts: the FIRST Trial

M Lins  1 , H Heuer, M Haude, P Braun, F Stahl, N Franz, R Simon; FIRST Trial Investigators
Affiliations
Multicenter Study

Distal embolic protection during percutaneous intervention of aorto-coronary venous bypass grafts: the FIRST Trial

M Lins et al. Clin Res Cardiol. 2007 Oct.

Abstract

Objective: Interventions in aorto-coronary venous bypass grafts (CABG) can cause acute procedural complications due to distal embolization of debris. In the FIRST (First European Investigation Regarding the Systematic use of the TriActiv device) multicenter trial the distal endovascular protection system TriActiv (Kensey Nash) was evaluated during intervention of CABG.

Methods: 195 patients in 17 centers in Germany with significant disease of a vein graft were enrolled. Inclusion and exclusion criteria were comparable to the SAFER trial.

Results: Acute procedural success was achieved in 98% of cases. Aspirated debris was found in 96.5% of patients. Primary endpoints (MACE at 30 days) occurred in 8.7% of all pts. (ITT). No patient died and 7.2% of patients suffered from MI. The rate of early revascularization was 1.5%. Secondary endpoints (MACCE at 30 days) were found in 9.2% and at hospital discharge in 8.7% of patients.

Conclusions: The TriActiv system is safe and effective. Normal post procedural flow can be preserved and the MACE rate is with 8.7% considerably low. The FIRST trial supports the growing belief that PCI of CABG should be performed with protection systems.

PubMed Disclaimer

References

    1. Am Heart J. 2005 Jun;149(6):1136 - PubMed
    1. Circulation. 2002 Dec 10;106(24):3063-7 - PubMed
    1. Circulation. 1999 Dec 14;100(24):2400-5 - PubMed
    1. J Am Coll Cardiol. 2005 Oct 18;46(8):1434-45 - PubMed
    1. J Am Coll Cardiol. 1998 Feb;31(2):241-51 - PubMed

Publication types

LinkOut - more resources